Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

VitaNova Life Sciences (YJGJ) Operating Expenses (2017 - 2026)

VitaNova Life Sciences (YJGJ) has disclosed Operating Expenses for 9 consecutive years, with $161633.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Operating Expenses rose 73.36% year-over-year to $161633.0, compared with a TTM value of $418429.0 through Oct 2025, up 19.24%, and an annual FY2025 reading of $367396.0, up 113.5% over the prior year.
  • Operating Expenses was $161633.0 for Q4 2025 at VitaNova Life Sciences, up from $101221.0 in the prior quarter.
  • Across five years, Operating Expenses topped out at $161633.0 in Q4 2025 and bottomed at $2899.0 in Q1 2021.
  • Average Operating Expenses over 5 years is $51319.4, with a median of $27777.0 recorded in 2021.
  • The sharpest move saw Operating Expenses plummeted 89.72% in 2023, then skyrocketed 1510.4% in 2024.
  • Year by year, Operating Expenses stood at $29991.0 in 2021, then tumbled by 75.33% to $7399.0 in 2022, then grew by 18.33% to $8755.0 in 2023, then skyrocketed by 964.92% to $93234.0 in 2024, then skyrocketed by 73.36% to $161633.0 in 2025.
  • Business Quant data shows Operating Expenses for YJGJ at $161633.0 in Q4 2025, $101221.0 in Q3 2025, and $75137.0 in Q2 2025.